InGen BioSciences Group, Announced Comprehensive Offering of in vitro Diagnostics in France With the Signature of Exclusive Distribution Partnerships With Quidel and Diagnostic Hybrids

InGen BioSciences Group, Announced Comprehensive Offering of in vitro Diagnostics in France With the Signature of Exclusive Distribution Partnerships With Quidel and Diagnostic Hybrids PR Newswire CHILLY-MAZARIN, France, August 20, 2012 CHILLY-MAZARIN, France, August 20, 2012 /PRNewswire/ -- InGen BioSciences, specialized in the development and commercialization of mono and multiparametric in vitro diagnostic tests announced exclusive partnerships with two key in vitro diagnostic companies, Quidel and Diagnostic Hybrids, for the distribution of their innovative tests on the French market. "These exclusive partnerships will allow InGen BioSciences to answer French biologists' unmet needs for early bacterial and viral infectious diseases as well as early and effective pregnancy detection, by providing doctors with advanced rapid tools for patient management," comments Isabelle Buckle, CEO of InGen BioSciences. Quidel Corporation (San Diego, California, US) a leading provider of rapid diagnostic testing solutions trusts InGen BioSciences expertise for the distribution of 14 rapid tests (acting in 3 to 15 minutes, depending on the test) on 7 different parameters in Infectious Diseases and Reproductive Health. "Quidel's products portfolio, marketed under the QuickVue® brand name, currently includes tests that aid in the diagnosis of Influenza, Respiratory Syncytial Virus (RSV), Strep A, Infectious Mononucleosis, H.